The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
KPd for patients with early RRMM: Primary analysis from the phase II SELECT trial
|
The phase II SELECT trial (NCT04191616) assessed the safety and efficacy of once-weekly carfilzomib plus pomalidomide and dexamethasone (KPd) in 52 adult patients with early relapsed/refractory multiple myeloma (RRMM) who were refractory to lenalidomide.1 Results of the primary analysis from this trial were published in Leukemia & Lymphoma by Perrot, et al.1 |
| Key learnings: |
|
Although the primary endpoint of overall response rate (ORR) was not met, the ORR was 57.7%, with a median duration of response of 20.3 months, highlighting the potential efficacy of KPd in patients with RRMM who are refractory to lenalidomide. |
|
Measurable residual disease (MRD) negativity was achieved in 9.6% of patients, indicating that KPd can effectively reduce MRD to undetectable levels in a subset of patients, a crucial prognostic factor for long-term remission. |
|
The median progression-free survival and overall survival among all patients was 11.1 months and 18.8 months, respectively. |
|
Treatment-emergent adverse events were consistent with the known safety profiles of carfilzomib and pomalidomide, with no new safety signals identified, suggesting that the KPd regimen is a viable option for heavily pretreated patients. |
|
The findings suggest an overall favorable benefit/risk profile of KPd as a salvage therapy for patients with multidrug-resistant RRMM relative to currently available therapies. |
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
